<div id="readability-page-1"><p><span>Certara (NASDAQ:CERT - Get Free Report)</span> was upgraded by stock analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report issued to clients and investors on Saturday.</p><ul><li>3 Momentum Stocks That Could Soar Post-Market Volatility</li></ul><p>A number of other brokerages have also weighed in on CERT. KeyCorp reduced their price objective on shares of Certara from $13.00 to $12.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday, January 8th. Stephens cut their price target on Certara from $15.00 to $12.00 and set an &#34;overweight&#34; rating on the stock in a research note on Friday, December 12th. Leerink Partners raised Certara from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $13.00 price objective for the company in a research report on Tuesday, January 6th. Morgan Stanley dropped their price objective on Certara from $16.00 to $12.00 and set an &#34;equal weight&#34; rating on the stock in a report on Thursday, December 18th. Finally, Barclays decreased their target price on Certara from $14.00 to $13.00 and set an &#34;overweight&#34; rating for the company in a research note on Monday, December 15th. One equities research analyst  has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned  a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $12.82.</p><p><b>Read Our Latest Report on Certara</b></p><h2>Certara Price Performance</h2><ul><li>Simulations Plus Stock Drops 15% Despite EPS Beat</li></ul><p>CERT stock opened at $7.23 on Friday. The business's 50-day moving average is $9.06 and its two-hundred day moving average is $10.28. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The firm has a market capitalization of $1.15 billion, a P/E ratio of 103.29 and a beta of 1.47. Certara has a 1 year low of $7.16 and a 1 year high of $15.69. </p><p>Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.03. The business had revenue of $104.62 million during the quarter, compared to the consensus estimate of $104.53 million. Certara had a return on equity of 5.18% and a net margin of 2.62%.During the same period in the previous year, the company posted $0.13 earnings per share.  Analysts anticipate that  Certara will post 0.28 earnings per share for the current fiscal year. </p><h2>Institutional Inflows and Outflows</h2><ul><li>Are These 3 Small Momentum Stocks Setting Up Big Gains?</li></ul><p>Institutional investors have recently bought and sold shares of the business. First Horizon Corp acquired a new stake in shares of  Certara during the third quarter worth about $30,000.  Versant Capital Management Inc lifted its position in  Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company's stock worth $35,000 after acquiring an additional 1,153 shares during the period.  Osaic Holdings Inc. lifted its position in  Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company's stock worth $41,000 after acquiring an additional 1,175 shares during the period.  Elevation Point Wealth Partners LLC purchased a new position in shares of  Certara in the 2nd quarter valued at approximately $59,000.  Finally, Global Retirement Partners LLC increased its holdings in shares of  Certara by 45.0% in the third quarter. Global Retirement Partners LLC now owns 5,636 shares of the company's stock valued at $69,000 after purchasing an additional 1,749 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Certara Company Profile</h2> (Get Free Report)<p>Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.  </p><p>The company's offerings are divided into software tools and consulting services.</p><h2>Read More</h2><ul><li>Five stocks we like better than Certara</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The day the gold market broke</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Your Bank Account Is No Longer Safe</li><li>He just nailed another gold prediction …</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Certara Right Now?</h2><p>Before you consider Certara, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.</p><p>While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CERT

<p>Wall Street Zen upgraded Certara (NASDAQ:CERT) from a "hold" to a "buy" rating. Other brokerages have also adjusted their price targets, with KeyCorp lowering it to $12.00 and Stephens to $12.00, while Leerink Partners set it at $13.00. Certara's stock opened at $7.23, with a market cap of $1.15 billion and a P/E ratio of 103.29. The company reported $0.14 EPS for the last quarter, exceeding estimates. Institutional investors hold 73.96% of the stock, which focuses on biosimulation software for drug development.</p>

Certara (NASDAQ:CERT) Raised to Buy at Wall Street Zen